

Gavin Wall 28 November 2013


QIAGEN's perspective in HAI testing



Epidemiology in Europe

artus QS-RGQ Menu

Nosocomial Infections - current trends










5



Questions



HAIs: a constant media presence



Source: Sued Deutsche Zeitung 2013, The Metro, The Guardian, Evening Standard









Overview

- Gram positive, toxin producing (A and B) bacterium
- The most frequent cause of bacterial healthcare-associated diarrhea
- *C. difficile* spores are easily transmitted via direct contact and aerosols.
- Occurs in 1/436 hospital admissions in Europe
- C. difficile infections adds 2,500-14,000 euro per hospital stay and extends hospitalisation from 6-21 days
- Total cost in Europe of **3 billion euro**

Diagnosis

- Symptomatic patients tested
- Lab evidence of **toxin-producing** *C. difficile* in stool
- Lab diagnosis is varied across Europe
- Only **1/3 of countries** have standard national screening algorithmns
- ELISA, cell cytotoxicity neutralization assay/ toxigenic culture and PCR can all identify toxinproducing *C. difficile*.
- Many labs employ a **2 step algorithm**
- Best standard laboratory test has not yet been established




Overview and Diagnosis

- Staphylococci spp are ubiquitous colonisers of the skin and mucous membranes.
- MRSA has been a growing threat since the 1960s and is a major cause of HAIs.
- Acquisition of resistance involves transfer of the staphylococcal cassette chromosome (SCCmec) from other organisms
- Traditional diagnostics: culture, chromogenic agar and other biochemical tests.
- Molecular methods have several advantages; they are more sensitive, less subjective and give a much quicker time from sample to result.
- Screening of high risk patients for MRSA carriage is mandatory in some EU countries

Epidemiology

Figure 2.6.4. *Staphylococcus aureus*: percentage of invasive (blood and cerebrospinal fluid) isolates resistant to meticillin, 2010



- Some countries have significantly reduced the MRSA rates due to national screening.
- Remains a public health priority
- Prevalence is still >25% in 8 countries
- Mainly in southern and eastern Europe

Source: Annual Epidemiological Report, ECDC, 2012




Overview and Diagnosis

- Enterococci belong to the normal bacterial flora of the GI tract of humans
- The third most common cause of bacterial HAIs
- Easily transmitted via direct contact with contaminated people or objects
- Diagnosis by conventional culture and antibiotic sensitivity methods
- Screening is not widespread across Europe
- Majority of screening is performed when an increase in resistance is observed
- Screening from anal/peri-anal swabs to determine carriage

Epidemiology

Figure 2.6.5. *Enterococcus faecium*: percentage of invasive (blood and cerebrospinal fluid) isolates resistant to vancomycin, 2010



Source: EARS-Net. Only data from countries reporting more than 10 isolates are shown



artus HAI portfolio on the QS-RGQ platform







artus C. difficile QS-RGQ Kit

• Toxin A and B detection

- Sample type: stool
- 72 (3x24) reactions

artus VanR QS-RGQ Kit

• vanA and vanB detection

- Sample type: perirectal or rectal swabs
- 72 (3x24) reactions

artus MRSA/MSSA QS-RGQ Kit


 MSSA, and MRSA (mecA and mecC) detection

- Sample type: nasal swab
- 72 (3x24) reactions

Launch dates	Q1 2013	Q2 2013	Q3 2013	Q4 2013	Q1 2014	Q2 2014	Q3 2014	Q4 2014	Remarks
artus C. difficile									CE: Q4/2013
artus VanR									CE: Q4/2013
artus MRSA/MSSA									CE: Q1/2014




Time-to-result



artus HAI assays meet the customers' need for fast and cost effective diagnostics





Fast and reliable results for better patient management



